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re Longitudinal, Natural
istory Studies the Next
tep in Genotype-Phenotype
ranslational Genomics in
ypertrophic Cardiomyopathy?*
ichael J. Ackerman, MD, PHD, FACC,
ara L. Van Driest, BA, Martijn Bos, MD
ochester, Minnesota
ver the past 15 years of translational genomics research,
normous strides have occurred in understanding the mo-
ecular underpinnings of hypertrophic cardiomyopathy
HCM). Clinical studies have shown that HCM is a
ommon disease (affecting 1 in 500 persons) with a highly
ariable phenotype (1,2). Clinical outcomes are documented
o range from an entirely asymptomatic course with normal
ongevity to chronic progressive heart failure or sudden
ardiac death (SCD). Genetic studies have led to the under-
tanding of HCM as principally a disease of the sarcomere or
ore specifically a disease of the cardiac myofilament. Cur-
See page 1737
ently, over 200 different HCM-associated mutations are
cattered throughout 8 different myofilament encoding genes,
ncluding: 1) thick filament comprised of MYH7-encoded
eta-myosin heavy chain, MYL2-encoded regulatory myosin
ight chain, and MYL3-encoded essential myosin light chain;
) intermediate filament comprised ofMYBPC3-encoded my-
sin binding protein C; and 3) thin filament comprised of
NNT2-encoded cardiac troponin T, TPM1-encoded alpha-
ropomyosin, TNNI3-encoded cardiac troponin I, and ACTC-
ncoded actin (2–6). Recent studies have also implicated
utations in Z-disk components, like muscle LIM protein
CSRP3) (7) and telethonin (TCAP) (8) as well as glycogen
torage diseases, such as AMP-activated protein kinase
amma 2 (PRKAG2) (9) and lysosome-associated mem-
rane protein 2 (LAMP2) (9) in the pathogenesis of HCM.
umerous genotype-phenotype correlative studies have
een reported, with conflicting and sometimes confusing
onclusions (4–6,10–15). One shortfall of these previous
tudies lies in the fact that nearly all of the genotype-
henotype data gathered to date have provided a “snapshot
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Departments of Medicine, Pediatrics, and Molecular Pharmacology and
xperimental Therapeutics and the Divisions of Cardiovascular Diseases and Pedi-s
tric Cardiology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester,
innesota.iew” of individual HCM patients with different causative
utations. There is a relative paucity of data correlating
enotype to disease progression over time.
LINICAL COURSE OF A FOUNDER
YBPC3 MUTATION
n this issue of the Journal, Kubo et al. (16) provide a concise
nd comprehensive longitudinal observation of the clinical
anifestations of a founder effect mutation involving the
YBPC3-encoded cardiac myosin binding protein C, which is
erhaps the most common genotype for myofilament-HCM
17). The V592fs/8 frameshift mutation was initially identified
n 15 of 94 Japanese probands. Analysis for this specific
utation in family members of these 15 probands identified 24
dditional V592fs/8-MYBPC3 genotype positive individuals.
hirty of the 39 genotype positive subjects had a demonstrable
CM phenotype based upon echocardiographic and/or elec-
rocardiographic findings. Disease penetrance for the V592fs/8
utation was 100% in patients over 50 years of age and 65% in
atients younger than 50 years of age. Over a mean follow up
eriod of 9.2  5.5 years, seven patients were hospitalized for
reatment of heart failure, three patients died of HCM-related
auses, and one patient had an implantable cardioverter-
efibrillator (ICD) discharge.
In contrast to some studies that described the course of
YBPC3-HCM as generally favorable (18–22), Kubo et al.
16) show that the course of patients with this particular
YBPC3 frameshift mutation often, although at an advanced
ge, leads to severe heart disease, which is supported by
revious observations from our center (6). We found that 63
16%) of 389 unrelated patients with HCM harbored a
utation in MYBPC3; a subset that was phenotypically indis-
inguishable from patients with thick filament-HCM (6).
otably, this Japanese founder mutation was not observed in
ur predominantly Caucasian cohort of HCM subjects.
One key aspect not addressed by this communication is
hat other common and intriguing characteristics of
YBPC3 may be contributing to the progression of disease
n Japanese patients. Besides being the most common
CM-associated gene, MYBPC3 has also been implicated
s the most common gene to harbor mutations leading to
rotein truncation (frameshift or nonsense mutation) (6).
hese mutations have been associated with a more severe
isease phenotype than those hosting missense mutations
n MYBPC3 (15,23). In addition, an estimated 5% to 10%
f patients with myofilament-HCM possess two distinct
CM-associated mutations, with MYBPC3 being the most
ikely myofilament gene to host one or both concomitant
arcomeric mutations (compound heterozygosity). Such pa-
ients with multiple sarcomeric/myofilament mutations have
een reported to be diagnosed at a younger age and to have
ore severe hypertrophy (6). Either of these factors could
ontribute to the malignant course seen in the patients de-
cribed in the present study by Kubo et al. (16).
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he methodology used by Kubo et al. (16) does open a new
oor in HCM genotype-phenotype research. The longitu-
inal study of a relatively large group of patients with an
dentical HCM-susceptibility mutation provides an oppor-
unity to explore the possibility that different mutations may
redispose to very different natural histories. Additionally,
ubo et al. (16) are in the unique position to use their
nding of a founder mutation among several unrelated
amilies to explore the effect of polymorphisms or disease
odifiers on the severity of the disease, as previously
emonstrated by Ortlepp et al. (24) in a single family with
YBPC3-HCM.
However, the results, as reflected accurately by Kubo et al.
16) in their study limitations, do not shed light on several
ther important issues. For example, what is the cellular
unction of myosin-binding protein C? Why is MYBPC3 in
omparison with other HCM-associated genes more sus-
eptible to micro-insertions and deletions resulting in pre-
ature truncations of this intermediate myofilament? Do
he patients with worse outcomes harbor additional HCM-
ssociated mutations? To what degree did lifestyle and
nvironment contribute to disease outcome? Although this
ongitudinal study is an important step to take, research in
his avenue alone will not fulfill the ultimate goal of
nderstanding the crucial question, “Why do these patients
ie?” Indeed, the answer to this question will come when
ata converge from several research fronts.
From the arena of HCM genomics, headway must be
ade in defining the full spectrum of HCM-causing and
CM-modifying genetic variants. Without this data, we
annot ascertain the full genetic context of any individual
atient with HCM. From clinical studies, we must deter-
ine the environmental and physiologic factors that play a
ole in disease progression. Hypertension, smoking, and
lcohol use are obvious candidates for environmental trig-
ers for disease progression, but in many studies these
ariables are either not assessed, or patients with these risk
actors are excluded from study. From the basic science
aboratories, a better understanding of the downstream effects,
ommon final pathways, and post-translational events occur-
ing in the cardiac myocytes with HCM-causing genetic
utations must be established. In addition, the cellular
unction(s) of both the MYBPC3-encoded intermediate
yofilament and other HCM-associated proteins must be
lucidated.
As the foundation of HCM genomics is built upon
ith further genetic, clinical, and basic science insights,
e can strive for critical insights that may one day lead
oward the effective prediction, treatment, and perhaps
ven the prevention of this disease. Kubo et al. (16)
hould be commended for providing an important step-
ing stone to pave the way toward achieving these lofty
oals.
1eprint requests and correspondence: Dr. Michael J. Ackerman,
udden Death Genomics Laboratory, Guggenheim 501, Mayo
linic, Rochester, Minnesota 55905. E-mail: ackerman.michael@
ayo.edu.
EFERENCES
1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE.
Prevalence of hypertrophic cardiomyopathy in a general population of
young adults. Echocardiographic analysis of 4,111 subjects in the
CARDIA Study. Coronary Artery Risk Development in (Young)
Adults. Circulation 1995;92:785–9.
2. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA
2002;287:1308–20.
3. Seidman JG, Seidman C. The genetic basis for cardiomyopathy:
from mutation identification to mechanistic paradigms. Cell 2001;
104:557–67.
4. Van Driest SL, Ellsworth EG, Ommen SR, Tajik AJ, Gersh BJ,
Ackerman MJ. Prevalence and spectrum of thin filament mutations in
an outpatient referral population with hypertrophic cardiomyopathy.
Circulation 2003;108:445–51.
5. Van Driest SL, Jaeger MA, Ommen SR, et al. Comprehensive analysis
of the beta-myosin heavy chain gene in 389 unrelated patients with
hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:602–10.
6. Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein
C mutations and compound heterozygosity in hypertrophic cardiomy-
opathy. J Am Coll Cardiol 2004;44:1903–10.
7. Geier C, Perrot A, Ozcelik C, et al. Mutations in the human muscle
LIM protein gene in families with hypertrophic cardiomyopathy.
Circulation 2003;107:1390–5.
8. Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in
hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll
Cardiol 2004;44:2192–201.
9. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases
presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:
362–72.
0. Ackerman MJ, Van Driest SV, Ommen SR, et al. Prevalence and
age-dependence of malignant mutations in the beta-myosin heavy
chain and troponin T gene in hypertrophic cardiomyopathy: a
comprehensive outpatient perspective. J Am Coll Cardiol 2002;39:
2042–8.
1. Jaaskelainen P, Kuusisto J, Miettinen R, et al. Mutations in the cardiac
myosin-binding protein C gene are the predominant cause of familial
hypertrophic cardiomyopathy in eastern Finland. J Mol Med 2002;80:
412–22.
2. Jaaskelainen P, Soranta M, Miettinen R, et al. The cardiac beta-
myosin heavy chain gene is not the predominant gene for hypertrophic
cardiomyopathy in the Finnish population. J Am Coll Cardiol 1998;
32:1709–16.
3. Van Driest SV, Ackerman MJ, Ommen SR, et al. Prevalence and
severity of “benign” mutations in the beta myosin heavy chain, cardiac
troponin-T, and alpha tropomyosin genes in hypertrophic cardiomy-
opathy. Circulation 2002;106:3085–90.
4. Morner S, Richard P, Kazzam E, et al. Identification of the genotypes
causing hypertrophic cardiomyopathy in northern Sweden. J Mol Cell
Cardiol 2003;35:841–9.
5. Erdmann J, Daehmlow S, Wischke S, et al. Mutation spectrum in a
large cohort of unrelated consecutive patients with hypertrophic
cardiomyopathy. Clin Genet 2003;64:339–49.
6. Kubo T, Kitaoka H, Okawa M, et al. Lifelong left ventricular
remodeling of hypertrophic cardiomyopathy caused by a founder
frameshift deletion mutation in the cardiac myosin-binding protein C
gene among Japanese. J Am Coll Cardiol 2005;46:1737–43.
7. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ.
Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin
Proc 2005;80:463–9.
8. Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ. Natural
history of hypertrophic cardiomyopathy in the elderly. J Am Coll
Cardiol 1990;16:821–6.9. Alders M, Jongbloed R, Deelen W, et al. The 2373insG mutation in
the MYBPC3 gene is a founder mutation, which accounts for nearly
22
2
2
2
1746 Ackerman et al. JACC Vol. 46, No. 9, 2005
Editorial Comment November 1, 2005:1744–6one-fourth of the HCM cases in the Netherlands. Eur Heart J
2003;24:1848–53.
0. Charron P, Dubourg O, Desnos M, et al. Clinical features and
prognostic implications of familial hypertrophic cardiomyopathy re-
lated to the cardiac myosin-binding protein C gene (comment).
Circulation 1998;97:2230–6.
1. Konno T, Shimizu M, Ino H, et al. A novel missense mutation in the
myosin binding protein-C gene is responsible for hypertrophic cardio-
myopathy with left ventricular dysfunction and dilation in elderly
patients. J Am Coll Cardiol 2003;41:781–6.
2. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the
gene for cardiac myosin-binding protein C and late-onset familialhypertrophic cardiomyopathy (comment). N Engl J Med 1998;
338:1248–57.
3. Erdmann J, Raible J, Maki-Abadi J, et al. Spectrum of clinical
phenotypes and gene variants in cardiac myosin-binding protein C
mutation carriers with hypertrophic cardiomyopathy. J Am Coll
Cardiol 2001;38:322–30.
4. Ortlepp JR, Vosberg HP, Reith S, et al. Genetic polymorphisms in
the renin-angiotensin-aldosterone system associated with expres-
sion of left ventricular hypertrophy in hypertrophic cardiomyopa-
thy: a study of five polymorphic genes in a family with a disease
causing mutation in the myosin binding protein C gene. Heart
2002;87:270–5.
